Associated Papers
Malignant adenomyoepithelioma with HRAS G13R mutation: A case report.
Kuwabara H et al.
Oncology Letters, 2026
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.
Hu Z et al.
Jacs Au, 2026
Precision oncology in Bulgaria: a prospective study of metastatic colorectal cancer patients.
Dimitrov G et al.
Cancer Treatment and Research Communications, 2026
Prognostic Significance of SOX9 and Its Combination With RAS and TP53 Mutations Following Colorectal Cancer Liver Metastasectomy.
Duan JL et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2025
Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis.
Shi X et al.
Journal of Advanced Research, 2025
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.
Kozakov D et al.
Frontiers in Medicine, 2025
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.
Yang X et al.
Journal of Hematology & Oncology, 2024
Molecular characterization of Chinese patients with small bowel adenocarcinoma.
Jin B et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.
Mosaferi Z et al.
Journal of Gastrointestinal Cancer, 2024
Real-world applications of the new grading system in lung adenocarcinoma: A study of 907 patients focusing on revealing the relationship between pathologic grade and genetic status.
Liu XL et al.
Annals of Diagnostic Pathology, 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Oudart JB et al.
Lung Cancer (amsterdam, Netherlands), 2024
Colibactin mutational signatures in NTHL1 tumor syndrome and MUTYH associated polyposis patients.
Terlouw D et al.
Genes, Chromosomes & Cancer, 2024
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
Chen M et al.
British Journal of Cancer, 2024
PROMER technology: A new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity.
Nam H et al.
Biology Methods & Protocols, 2024
Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants.
Silverman I et al.
Frontiers in Molecular Biosciences, 2024
Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences.
Chen W et al.
Nature Biomedical Engineering, 2023
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T et al.
Cancer Medicine, 2023
Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
Friedman CF et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
The Genomic Landscape of Colorectal Cancer in the Saudi Arabian Population Using a Comprehensive Genomic Panel.
Alsolme E et al.
Diagnostics (basel, Switzerland), 2023
Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.
Afrăsânie VA et al.
International Journal of Molecular Sciences, 2023
Generation of novel complete HLA class I monoallelic cell lines used in an MHC stabilization assay for neoantigen evaluation.
Iizuka A et al.
Oncology Letters, 2023
KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies.
Ottaiano A et al.
Cancers, 2023
Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.
Sayagués JM et al.
International Journal of Molecular Sciences, 2023
KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z et al.
Journal of Clinical Laboratory Analysis, 2023
Mutations in Classical Signaling Pathways and Their Functional Impact in Microsatellite Instability High Colorectal Cancer.
Shi S et al.
Genetic Testing and Molecular Biomarkers, 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.
Veccia A et al.
Targeted Oncology, 2023
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK et al.
Npj Precision Oncology, 2022
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics.
Roma C et al.
Diagnostics (basel, Switzerland), 2022
Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines.
da Silva-Oliveira RJ et al.
International Journal of Molecular Sciences, 2022
An In Vivo Inflammatory Loop Potentiates KRAS Blockade.
Arendt KAM et al.
Biomedicines, 2022
Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach.
S UK et al.
Journal of Biomolecular Structure & Dynamics, 2022
KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients.
Wang S et al.
Frontiers in Molecular Biosciences, 2022
Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population With Non-small Cell Lung Cancer.
Kahraman Çetin N et al.
Balkan Medical Journal, 2021
HPLC method to resolve, identify and quantify guanine nucleotides bound to recombinant ras GTPase.
Hannan JP et al.
Analytical Biochemistry, 2021
Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors.
Min BJ et al.
Cancers, 2021
Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer.
Rodríguez-Casanova A et al.
Journal of Clinical Medicine, 2021
Expanding mutational spectrum of HRAS by a patient with Schimmelpenning-Feuerstein-Mims syndrome.
Luo Q et al.
The Journal of Dermatology, 2021
Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics.
Roepman P et al.
The Journal of Molecular Diagnostics : Jmd, 2021
Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).
Mascarenhas E et al.
Thoracic Cancer, 2021
Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
Zhu D et al.
Bmc Cancer, 2021
Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
Guo T et al.
Cancer Management and Research, 2021
Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China.
Zhou Y et al.
Frontiers in Oncology, 2021